Bernard Gilly

Bernard Gilly serves as Group CEO at GenSight Biologics. GenSight Biologics operates in the research sector with approximately 34.0 employees. The company is headquartered in Paris, Ile-de-France. GenSight Biologics generates annual revenue of 1401000.0.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • We have verified contacts for 3 executives at GenSight Biologics.
• • 4,101 executive contacts are available in Ile-de-France.
• • Our database includes 201,469 c suite-level executives.

Outlook Microsoft Office 365 Viewpoint AI

biotechnology research gene therapy retinal diseases neurodegenerative diseases optogenetics inherited blindness clinical trials mitochondrial targeting sequence vision restoration leber hereditary optic neuropathy retinitis pigmentosa geographic atrophy ophthalmology biotechnology aav vectors drug development rare diseases patient solutions clinical development ophthalmic therapies genetically modified therapies regulatory affairs biopharmaceuticals medical devices scientific research biotech industry therapeutic strategies pharmaceutical development ocular diseases biotech investments genetic engineering clinical operations pre-clinical studies pharmacovigilance market access biotech commercialization healthcare innovation medical biotechnology eye care vision treatments biotech collaborations research & development investor relations biotech funding advanced therapies scientific excellence biomedical research ophthalmologic interventions health care health wellness & fitness hospital & health care

MG

Marion Ghibaudo Chief Technical Officer at GenSight Biologics

EC

Erika Chassagne Assistante du CEO at GenSight Biologics

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

Outreach Guidance — research Sector

Executives like Bernard Gilly in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at GenSight Biologics.

Bernard Gilly's Position in the MessageCEO Database

• •Bernard Gilly is 1 of 3 verified executive contacts we track at GenSight Biologics.
• •2,871 verified executive contacts in research are in the MessageCEO database.
• •4,045 verified executive contacts in Ile-de-France are in the database.
• •41 verified contacts work at research companies in the 34.0 employee range (same size as GenSight Biologics).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Bernard Gilly directly?

Bernard Gilly's verified email address is available to MessageCEO Pro subscribers. They currently serve as Group CEO at GenSight Biologics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Bernard Gilly work for?

Bernard Gilly is Group CEO at GenSight Biologics, a company in the research sector with 34.0 employees. The company is based in Paris, Ile-de-France.

Can I pitch or sell to Bernard Gilly?

As Group CEO at GenSight Biologics, Bernard Gilly is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Bernard Gilly directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Bernard Gilly in?

Bernard Gilly works in the research industry as Group CEO at GenSight Biologics. MessageCEO provides verified contact information for executives across all major industries.

Is Bernard Gilly's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Bernard Gilly's profile is kept up-to-date with the latest available information.

Last updated: July 22, 2026